DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Arthritis, Juvenile Rheumatoid

Intervention: Celecoxib (Drug); Naproxen (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis

Clinical Details

Official title: A Phase 4, 6-Week, Randomized Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change from Baseline to Week 6/Final visit in Systolic Blood Pressure

Secondary outcome:

Change from Baseline to Weeks 2 and 4 in SBP

Change from Baseline to Weeks 2, 4, and 6/Final visit in DBP

Change from Baseline to Week 6/Final visit in the Parent's and Subject's Assessment of Overall Well-Being;

Effect of celecoxib and naproxen on blood pressure measured by Ambulatory Blood Pressure Monitoring (ABPM) in subjects with JIA

Adverse event profile and GI tolerability of treatment with celecoxib vs. treatment with naproxen in subjects with JIA

Eligibility

Minimum age: 2 Years. Maximum age: 18 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Polyarticular (both rheumatoid factor positive and rheumatoid factor

negative),oligoarticular and extended oligoarticular JIA for ≥3 months meeting the International League of Associations for Rheumatology (ILAR) criteria for Juvenile Idiopathic Arthritis (JIA)

- Subjects with Systemic JIA with active arthritis in at least 1 joint but without

active systemic features are eligible

- ≥2 years of age and <18 years of age prior to the Baseline visit

- Body weight ≥10 kg at the Baseline visit

- Candidate for chronic NSAID therapy in the Investigator's judgment

Exclusion Criteria:

- Psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis

types of JIA

- Active systemic features over the prior 12 weeks in children with systemic Juvenile

Idiopathic Arthritis (JIA)

- Subjects with psoriatic arthritis, enthesitis-related arthritis, and undifferentiated

arthritis should be excluded

- Subjects with active Systemic JIA should not be enrolled

Locations and Contacts

Pfizer Investigational Site, San Jose 00000, Costa Rica

Pfizer Investigational Site, Manila 1000, Philippines

Pfizer Investigational Site, Manila 1008, Philippines

Pfizer Investigational Site, Moscow 105077, Russian Federation

Pfizer Investigational Site, Moscow 119992, Russian Federation

Pfizer Investigational Site, Smolensk 214000, Russian Federation

Pfizer Investigational Site, Smolensk 214019, Russian Federation

Pfizer Investigational Site, Belgrade 11000, Serbia

Pfizer Investigational Site, Nis 18000, Serbia

Pfizer Investigational Site, CH-1011 Lausanne, Switzerland

Pfizer Investigational Site, CH-8032 Zuerich, Switzerland

Pfizer Investigational Site, Kharkiv 61153, Ukraine

Pfizer Investigational Site, Kiev 04050, Ukraine

Pfizer Investigational Site, Kyiv 04209, Ukraine

Pfizer Investigational Site, Simferopol 95034, Ukraine

Pfizer Investigational Site, Zaporizhzhya 69063, Ukraine

Pfizer Investigational Site, Tucson, Arizona 85704, United States

Pfizer Investigational Site, Little Rock, Arkansas 72202, United States

Pfizer Investigational Site, San Diego, California 92123, United States

Pfizer Investigational Site, Hartford, Connecticut 06106, United States

Pfizer Investigational Site, Washington, District of Columbia 20010, United States

Pfizer Investigational Site, Delray Beach, Florida 33484, United States

Pfizer Investigational Site, Miami, Florida 33155-3009, United States

Pfizer Investigational Site, Pretoria, Gauteng Province 0001, South Africa

Pfizer Investigational Site, Honolulu, Hawaii 96826, United States

Pfizer Investigational Site, Honolulu, Hawaii 96813, United States

Pfizer Investigational Site, Louisville, Kentucky 40202, United States

Pfizer Investigational Site, San Borja, Lima L41, Peru

Pfizer Investigational Site, San Isidro, Lima L27, Peru

Pfizer Investigational Site, Omaha, Nebraska 68114, United States

Pfizer Investigational Site, Omaha, Nebraska 68198-5456, United States

Pfizer Investigational Site, Akron, Ohio 44308, United States

Pfizer Investigational Site, Hershey, Pennsylvania 17033, United States

Pfizer Investigational Site, Santiago, RM 8380418, Chile

Pfizer Investigational Site, Concepcion, VIII Region 4070038, Chile

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: September 2009
Last updated: January 29, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017